摘要
目的:系统评价参松养心胶囊联合胺碘酮治疗冠心病心律失常的疗效与安全性。方法:检索建库以来到2019年3月1日Pubmed、Web of science、Cochrane Library、万方、维普、中国知网等电子数据库所有应用参松养心胶囊联合胺碘酮治疗冠心病心律失常的临床随机对照试验(RCT),排除不符合标准的资料后,应用RevMan 5.3软件对符合标准的资料进行Meta分析。结果:参松养心胶囊联合胺碘酮对比单用胺碘酮临床疗效(RR=1.22,95%Cl[1.17,1.27],I 2=0%,P<0.00001),心电图疗效(RR=1.27,95%Cl[1.16,1.40],I 2=0%,P<0.00001),血流动力学疗效:血细胞沉降率(MD=-4.38,95%Cl[-5.13,-3.64],I 2=0%,P<0.00001),红细胞比容(MD=-11.14,95%Cl[-12.04,-10.24],I 2=0%,P<0.00001),纤维蛋白原(MD=-17.80,95%C l[-40.18,4.58],I 2=94%,P=0.12),血浆比黏度(MD=-0.75,95%Cl[-0.96,-0.55],I 2=86%,P<0.00001),不良反应发生率(RR=0.46,95%Cl[0.32,0.65],I 2=5%,P<0.00001)。结论:相比于单用胺碘酮,参松养心胶囊联合胺碘酮治疗冠心病心律失常疗效显著且安全性更高。
Objective:To systematically evaluate the efficacy and safety of Shensong Yangxin Capsule combined with amiodarone in the treatment of coronary heart disease arrhythmia.Methods:Search for electronic databases such as Pubmed,Web of science,Cochrane Library,Wanfang,Weipu,and China Knowledge Network.From the establishment of the database to March 1,2019,all the clinical randomized controlled trial(RCT)related to application of Shensong Yangxin Capsule combined with amiodarone in the treatment of coronary heart disease arrhythmia was collected to perform meta-analysisby RevMan5.3 software after excluding non-compliant ones.Results:Shensong Yangxin Capsule combined with amiodarone compared with amiodarone alone:RR=1.22,95%Cl[1.17,1.27],I 2=0%,P<0.00001;ECG effect:RR=1.27,95%Cl[1.16,1.40],I 2=0%,P<0.00001;hemodynamics hematocrit rate:MD=-4.38,95%Cl[-5.13,-3.64],I 2=0%,P<0.00001;hematocrit:MD=-11.14,95%Cl[-12.04,-10.24],I 2=0%,P<0.00001;fibrinogen:MD=-17.80,95%Cl[-40.18,4.58],I 2=94%,P=0.12;plasma specific viscosity:MD=-0.75,95%Cl[-0.96,-0.55],I 2=86%,P<0.00001;incidence of adverse reactions:RR=0.46,95%Cl[0.32,0.65],I 2=5%,P<0.00001.Conclusion:Compared with amiodarone alone,Shensong Yangxin Capsule combined with amiodarone is effective and safe in the treatment of coronary heart disease arrhythmia.
作者
乔利杰
朱明军
李彬
郝轩轩
卫靖靖
马腾
QIAO Li-jie;ZHU Ming-jun;LI Bin;HAO Xuan-xuan;WEI Jing-jing;MA Teng(Henan University of Traditional Chinese Medicine,Zhengzhou 450046,China;The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China)
出处
《中国中医基础医学杂志》
CAS
CSCD
北大核心
2020年第10期1505-1510,共6页
JOURNAL OF BASIC CHINESE MEDICINE
基金
国家重点基础研究发展计划(2015CB554401)-基于病证结合的气血相关理论研究
国家自然科学基金资助项目(81503419)-参附益心颗粒通过PGC-1α信号通路改善慢性心衰心肌线粒体能量代谢的机制研究
国家自然科学基金资助项目(81373853)-参附益心颗粒通过抑制AngⅡ改善心梗后心衰大鼠心肌代谢重构的机制研究
国家自然科学基金资助项目(81603466)-参附益心颗粒通过调控miRNA-21抑制心梗后心室重构的作用和机制研究”
国家自然科学基金资助项目(81603432)-参附益心颗粒通过调节心肌ATP敏感钾通道改善心肌梗死后心衰大鼠的能量代谢研究
河南省创新型科技团队(C20130050)。
关键词
参松养心胶囊
胺碘酮
冠心病
心律失常
META分析
Shensong Yangxin capsule
Amiodarone
Coronary heart disease
Arrhythmia
Meta-analysis
